FDA OKs Merck’s Keytruda for treatment-resistant type of skin cancer
The FDA approves Merck’s (NYSE:MRK) Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma, the second most common form of skin cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.